Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | April 24, 2017

Top 5 Hottest Cardiology Technology Topics - No. 1 FDA Slams Abbott/St. Jude

I keep close watch on our magazine’s digital analytics for both our website and social media, and it shows me in real time what readers think are the hottest topics in cardiac technology. Here is a top 5 list of some of the most note-worthy recent news items:

1. FDA Harshly Criticizes Abbott, St. Jude For Failure to Address EP Device Safety

The U.S. Food and Drug Administration (FDA) sent the most strongly worded warning letter I have seen to Abbott/St. Jude Medical (SJM) in April, blasting the company for failure to address several issues with its implantable electrophysiology (EP) devices. This included failure to take corrective action for flawed batteries in these devices, shipping recalled products to customers that were then implanted into patients, and failure to adequately protect patients with implanted EP devices from cyber-attacks. The warning letter, issued April 12, was written in response to an FDA inspection that revealed major problems with the Fortify, Unify and Assura (including Quadra) implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, and the [email protected] monitoring system used in combination with these devices. “These devices are adulterated…in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage or installation are not in conformity with the current good manufacturing practice requirements,” wrote U.S. Public Health Service Capt. Sean M. Boyd, MPH, deputy director for regulatory affairs, Office of Compliance, Center for Devices and Radiological Health, in the warning letter. “The specific violations noted in this letter and in the inspectional observations issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.”

 

2. FDA Clears First Dedicated Coronary Bifurcation Stent

The FDA granted pre-market approval (PMA) for the Tryton Side Branch Stent for the treatment of coronary bifurcation lesions involving large side branches. It is the first dedicated bifurcation device to receive regulatory approval in the United States and addresses an unmet need in coronary interventions. About 20-30 percent of patients undergoing percutaneous coronary interventions (PCI) have a bifurcation lesion. Provisional stenting of the main branch is the current standard of care, but in many cases the side branch is not stented, leaving it vulnerable to complications like occlusion requiring bailout stenting. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

 

3. New Cardiogenic Shock Protocol Dramatically Increases Survival Rates

Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing rapid percutaneous hemodynamic support before treating the cause of a heart attack, according to a new analysis that included more than 15,000 patients across the United States. Doctors in Detroit increased survival rates from 50 to 84 percent by following the implementation of a new protocol of using a percutaneous ventricular assist device first, prior to PCI. William W. O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit, presented the data at ACC.17. He also spoke with me in a video interview. 

 

4. ACC 2017 Late-Breaking Trials

Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presented at ACC.17 in March, with links to articles specific to many of the trial presentations.

 

5. Cardiovascular Systems Initiates Voluntary Recall of Atherectomy Saline Infusion Pump

Cardiovascular Systems Inc. (CSI) announced April 18 it had initiated a voluntary recall of its 7-10014 Saline Infusion Pump. CSI initiated a customer communication of the recall by letter and informed customers that they may continue to use the affected pumps until they receive a replacement. The pumps provide saline and lubricant infusion during orbital atherectomy procedures and electrical power to the orbital atherectomy device. CSI has determined that electromagnetic interference present in the hospital environment may cause the pumps to switch to standby mode during use, requiring the pump to be reset prior to continuing treatment. 

Related Content

Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
DABRA Excimer Laser System Demonstrates Success in Treating PAD
News | Cath Lab | February 27, 2019
Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s...
Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Scientists Discover New Heart Attack Repair Pathway

A macrophage immune cell, with a dead cell (pink) that has been eaten, and a mitochondrion (green) between the dead cell and the nucleus. The study’s findings indicate that what the macrophage eats is taken up by the mitochondrion, which in turn communicates with the nucleus to activate the macrophage to promote tissue repair. Image courtesy of Northwestern Medicine.

News | Cath Lab | January 30, 2019
Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack....
Overlay Init